Jason Hurt

Company: OranoMed

Job title: Chief Executive Officer

Seminars:

Clinical Experience with 212Pb-Compounds 2:00 pm

Common treatment emergent adverse events in NETs Renal Toxicity: How is it defined and what can we do about it? Phase 1 Study of 212Pb-DOTAM-GRPR1 in Adult Subjects with Recurrent or Metastatic GRPR-expressing TumorsRead more

day: Day one Track A PM

Clinical Experience with 212Pb-Compounds 2:00 pm

Common treatment emergent adverse events in NETs Renal Toxicity: How is it defined and what can we do about it? Phase 1 Study of 212Pb-DOTAM-GRPR1 in Adult Subjects with Recurrent or Metastatic GRPR-expressing TumorsRead more

day: Day one Track B PM